Short answer
Lexeo Therapeutics, Inc. (LXEO) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$26M
- +0.9% YoY · −28.1% QoQ
- EPS (diluted)
- −$0.30
- +44.4% YoY · −20.0% QoQ
Source: XBRL data from the Lexeo Therapeutics, Inc. (LXEO) Q2 2026 10-Q on SEC EDGAR. USD.
Lexeo Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added administration risk: FDA staffing and leadership changes could delay product development or commercialization
- Net loss $46.1 million for six months ended June 30, 2026, with accumulated deficit of $426.2 million
- Regulatory risk: evolving gene-therapy requirements and uncertain FDA or EMA review timelines for novel capsids
- Near-term clinical risk: low-prevalence diseases may delay patient enrollment and regulatory approvals
- Liquidity risk: $234.2 million cash, equivalents and U.S. Treasury securities expected to fund operations into 2028
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Lexeo Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.